Rosas-Cabral Alejandro, Irigoyen Lourdes, Alvarado Lilia, Vela-Ojeda Jorge, Ayala-Sánchez Manuel, Tripp-Villanueva Francisco, Sánchez Evelia, Gonzalez-Llaven José, Gariglio Patricio
Rev Invest Clin. 2003 Jul-Aug;55(4):423-8.
Chronic myeloid leukemia (CML) is characterized by a chromosomal translocation t(9; 22) resulting in the chimeric ber-abl oncogene that encode for the p210 protein which has an increased tyrosine kinase activity. The fusion part of this protein contains a novel aminoacid sequence. If peptides derived from this leukemia-specific part of p210 are expressed in the context of HLA molecules on malignant cells this may elicit immunologically specific responses. Recent studies using synthetic peptides identical to the bcr-abl fusion region revealed that breakpoint specific peptides are capable of binding to the class I molecules HLA-A3, -A11 and -B8. It has been shown that individuals expressing HLA-A3 or HLA-B8 have a diminished risk for development of CML in Caucasoid populations. Other authors have reported a statistically significant increase in the frequency of Cw3 and Cw4 antigens in Causcasoids and European CML patients. These data suggested that Cw3 and Cw4 may be markers for CML susceptibility on these populations.
To asses a possible susceptibility effect of these HLA molecules we studied 63 CML Mexican Mestizo patients and 746 healthy subjects for the distribution of HLA class I and class II molecules.
The gene products that showed statistically significant differences between CML patients and controls were DR14, DR3, Cw3 and Cw4. DR14 and DR3 were significantly increased in the patients group with respect to the controls group (DR14 antigen frequency: 3.17% vs. 0.29%; p = 0.03; DR3 20.63% vs. 8.33%; p = 0.0001). Cw3 and Cw4 were significantly decreased in the patient group (Cw3 26.9% vs. 49.11%; p = 0.03; Cw4 antigen frequency 23.8% vs. 86.28%; p = 0.0000001). The relative risk for DR14 was 10.48 (95% CI 1.52-79.29) and for DR3 was 3.96 (95% CI 2.05-7.71). The relative risk for Cw3 was 0.38 (95% CI 0.08-1.79) and for Cw4 was 0.11 (95% CI 0.048-0.81).
These results suggest that the development of CML is apparently associated with HLA phenotypes specific to each population, and indicate that Cw3 and Cw4 expression may result in a protective effect on the CML acquisition on Mexican Mestizo population probably by bcr-abl breakpoint peptides presentation through these HLA molecules.
慢性髓性白血病(CML)的特征是发生染色体易位t(9; 22),产生嵌合的bcr-abl癌基因,该基因编码具有增强酪氨酸激酶活性的p210蛋白。这种蛋白质的融合部分包含一个新的氨基酸序列。如果源自p210白血病特异性部分的肽在恶性细胞上的HLA分子背景下表达,这可能引发免疫特异性反应。最近使用与bcr-abl融合区域相同的合成肽的研究表明,断点特异性肽能够与I类分子HLA-A3、-A11和-B8结合。已经表明,在白种人群体中,表达HLA-A3或HLA-B8的个体患CML的风险降低。其他作者报告说,在白种人和欧洲CML患者中,Cw3和Cw4抗原的频率有统计学意义的增加。这些数据表明,Cw3和Cw4可能是这些人群中CML易感性的标志物。
为了评估这些HLA分子可能的易感性影响,我们研究了63例墨西哥梅斯蒂索CML患者和746名健康受试者的HLA I类和II类分子分布。
在CML患者和对照组之间显示出统计学显著差异的基因产物是DR14、DR3、Cw3和Cw4。与对照组相比,患者组中DR14和DR3显著增加(DR14抗原频率:3.17%对0.29%;p = 0.03;DR3 20.63%对8.33%;p = 0.0001)。患者组中Cw3和Cw4显著降低(Cw3 26.9%对49.11%;p = 0.03;Cw4抗原频率23.8%对86.28%;p = 0.0000001)。DR14的相对风险为10.48(95%可信区间1.52 - 79.29),DR3的相对风险为3.96(95%可信区间2.05 - 7.71)。Cw3的相对风险为0.38(95%可信区间0.08 - 1.79),Cw4的相对风险为0.11(95%可信区间0.048 - 0.81)。
这些结果表明,CML的发生显然与每个群体特有的HLA表型相关,并表明Cw3和Cw4的表达可能对墨西哥梅斯蒂索人群中CML的获得产生保护作用,可能是通过这些HLA分子呈递bcr-abl断点肽。